Silicon Therapeutics (“SITX”) is a privately-held, physics-driven integrated drug discovery company in the preclinical IND stage targeting innate immunity to start, but with the capability to move into many other franchise opportunities. The Company’s initial pipeline is focused on modulation of the innate immune system to “light the spark” within immunologically cold tumors by using its physics-enabled drug discovery engine for the design of small molecule therapeutics and the lead program is in late stage preclinical studies. SITX’s discovery efforts as well as physics-based platform are all completely in-house, with a full wet lab as well as a team of over 25 experienced R&D professionals spanning biology, biochemistry, chemistry, biophysics (NMR + X-ray) & preclinical sciences. SITX’s engine leverages quantum mechanics and molecular dynamics, which are deployed on its own internal super computer composed of over 400 GPU’s and FPGA’s and allows SITX to accurately simulate the physical motion and properties of biological targets at an atomistic level resolution. The platform is completely proprietary to SITX and was built from the ground up with the purpose of addressing difficult targets and using simulations to break through bottlenecks that has plagued traditional drug discovery approaches on such targets. It is currently the ONLY company which owns the entire spectrum of physics-driven drug discovery from chip-to-clinic with a team of over 40 individuals in Boston.
The Company’s initial focus in on innate immunity and its pipeline is currently composed of one project entering into IND-enabling studies, another one entering hit-to-lead and two more ramping up. It’s unique advantage in designing small molecules using all atom simulations has allowed it to advance a systemically available small molecule STING agonist into a preclinical development. The program is ramping up for IND enabling studies entry to the clinic in 2020. This differentiated product can be administered systemically via an IV dose and has single agent effects in early mouse efficacy studies using PD1 resistant tumor models and is a “rule-of-5” compliant small molecule. Beyond this one program, the Company is also advancing an ADAR inhibitor which can be considered an innate immune check-point as well as a multitude of targets that explore Innate Immunity’s role in cancer biology.
SITX was founded out of the BIDMC in late 2016 and has raised ~50mm USD to date from leading investors including Sequoia & Chengwei Capital. The Company’s investors are long-term, premier brands that have the capability to hold businesses for decades and are believers in SITX’s mission and physics-driven approach.
Silicon Therapeutics is seeking an innovative and motivated scientist to spearhead the design, development and execution of human and/or mouse immunological assays to support STX’s pipeline of novel small molecule therapeutics in immuno oncology and immunology.
- Work closely with project leads and discovery scientists to identify and develop robust immunological assays to support programs through all stages of preclinical development
- Identify relevant sources of primary immune cells and establish robust SOPs for single and multi-cellular assays required for screening compounds, determining MOA and validating biomarkers
- Provide expertise in functional area of immunology/immuno oncology and work independently to design, conduct, and analyze
- Interpret data clearly and concisely both verbally and in documents and present results in an organized manner.
- Deliver critical path biology results and high-quality scientific data packages to meet project and organizational goals.
- Prioritize, manage time efficiently, and implement creative solutions to meet program needs.
- Lead key activities and establish and expand internal wet lab capabilities at our growing Boston site to drive projects from discovery to first-time-in-human.
Required Skills and Qualifications:
- Ph.D. in Immunology or Immuno-Pharmacology related discipline. Industry experience is preferred but not required; OR, Bachelor’s or Master’s degree in immunology, immuno-oncology or related field with 5-7+ years of Biotech or Pharmaceutical experience in immunology or immuno-oncology focus
- A thorough knowledge of immunology and a strong background in oncology
- Hands-on experience with various in vitro/ex vivo immunology-related techniques, including immune cell isolation & manipulation, cytokine/chemokine profiling, and phenotypic characterization of immune cells
- Research expertise in the field of innate immunity, including hands-on experiences with functional characterization of dendritic cells, macrophages, and/or NK cells is preferred
- Demonstrated expertise in high-dimensional flow cytometry to phenotypically characterize immune cells from human and murine tissue samples, including both surface and intracellular staining is required
- Proficiency in general mammalian cell culture, transient/ stable cell line generation, RT-PCR/qPCR, PAGE, Western-blotting
- Hands on experience in gene modulating technologies, such as RNAi and/or CRISPR/Cas9, recombinant expression construct design & cloning, is plus
- Strong communication skills and ability to conduct research in a cross-functional team environment.
- Demonstrated independence in experimental design, execution, data analysis, and troubleshooting
- Ability to mentor junior scientists and colleagues on best laboratory practices is highly valued
- Commitment to continual improvement by reading and applying the latest scientific literature, methodologies and technology where appropriate